Exploring new frontiers: Sirolimus as a pharmacokinetic modulator in advanced cancer patients

Massimiliano Veroux, Tiziano Tallarita, Daniela Corona, Antonio D'Assoro, Pierfrancesco Veroux

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The mTOR pathway mediates many biologic functions such as transcriptional and translational control, and is a target for anticancer drug development. mTOR inhibitors, such as sirolimus (SRL), display immunosuppressive and antiproliferative properties, and the use of SRL in kidney transplant recipients reduces the risk of post-transplant cancer. However, its use in advanced cancer patients has not been fully evaluated. The authors review the study by Cohen et al., evaluating the dose for oral, weekly SRL alone or in combination with grapefruit juice or ketoconazole to achieve the desired whole-blood concentration with antitumoral activity. This study demonstrates that SRL can be feasibly administered orally once weekly and displays a similar pharmacokinetic profile compared with other mTOR inhibitors. This study encouraged the use of SRL in advanced cancer patients and can stimulate clinical trials with a larger number of patients, evaluating the role of SRL as a new targeted therapy in cancer patients.

Original languageEnglish (US)
Pages (from-to)17-20
Number of pages4
JournalExpert review of anticancer therapy
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Sirolimus
Pharmacokinetics
Neoplasms
Citrus paradisi
Ketoconazole
Immunosuppressive Agents
Clinical Trials
Transplants
Kidney
Pharmaceutical Preparations

Keywords

  • cancer
  • grapefruit juice
  • ketoconazole
  • once weekly
  • oral
  • sirolimus
  • transplantation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Exploring new frontiers : Sirolimus as a pharmacokinetic modulator in advanced cancer patients. / Veroux, Massimiliano; Tallarita, Tiziano; Corona, Daniela; D'Assoro, Antonio; Veroux, Pierfrancesco.

In: Expert review of anticancer therapy, Vol. 13, No. 1, 01.01.2013, p. 17-20.

Research output: Contribution to journalReview article

Veroux, Massimiliano ; Tallarita, Tiziano ; Corona, Daniela ; D'Assoro, Antonio ; Veroux, Pierfrancesco. / Exploring new frontiers : Sirolimus as a pharmacokinetic modulator in advanced cancer patients. In: Expert review of anticancer therapy. 2013 ; Vol. 13, No. 1. pp. 17-20.
@article{fa872bf548964088a5d6c64ae4386e71,
title = "Exploring new frontiers: Sirolimus as a pharmacokinetic modulator in advanced cancer patients",
abstract = "The mTOR pathway mediates many biologic functions such as transcriptional and translational control, and is a target for anticancer drug development. mTOR inhibitors, such as sirolimus (SRL), display immunosuppressive and antiproliferative properties, and the use of SRL in kidney transplant recipients reduces the risk of post-transplant cancer. However, its use in advanced cancer patients has not been fully evaluated. The authors review the study by Cohen et al., evaluating the dose for oral, weekly SRL alone or in combination with grapefruit juice or ketoconazole to achieve the desired whole-blood concentration with antitumoral activity. This study demonstrates that SRL can be feasibly administered orally once weekly and displays a similar pharmacokinetic profile compared with other mTOR inhibitors. This study encouraged the use of SRL in advanced cancer patients and can stimulate clinical trials with a larger number of patients, evaluating the role of SRL as a new targeted therapy in cancer patients.",
keywords = "cancer, grapefruit juice, ketoconazole, once weekly, oral, sirolimus, transplantation",
author = "Massimiliano Veroux and Tiziano Tallarita and Daniela Corona and Antonio D'Assoro and Pierfrancesco Veroux",
year = "2013",
month = "1",
day = "1",
doi = "10.1586/era.12.151",
language = "English (US)",
volume = "13",
pages = "17--20",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Exploring new frontiers

T2 - Sirolimus as a pharmacokinetic modulator in advanced cancer patients

AU - Veroux, Massimiliano

AU - Tallarita, Tiziano

AU - Corona, Daniela

AU - D'Assoro, Antonio

AU - Veroux, Pierfrancesco

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The mTOR pathway mediates many biologic functions such as transcriptional and translational control, and is a target for anticancer drug development. mTOR inhibitors, such as sirolimus (SRL), display immunosuppressive and antiproliferative properties, and the use of SRL in kidney transplant recipients reduces the risk of post-transplant cancer. However, its use in advanced cancer patients has not been fully evaluated. The authors review the study by Cohen et al., evaluating the dose for oral, weekly SRL alone or in combination with grapefruit juice or ketoconazole to achieve the desired whole-blood concentration with antitumoral activity. This study demonstrates that SRL can be feasibly administered orally once weekly and displays a similar pharmacokinetic profile compared with other mTOR inhibitors. This study encouraged the use of SRL in advanced cancer patients and can stimulate clinical trials with a larger number of patients, evaluating the role of SRL as a new targeted therapy in cancer patients.

AB - The mTOR pathway mediates many biologic functions such as transcriptional and translational control, and is a target for anticancer drug development. mTOR inhibitors, such as sirolimus (SRL), display immunosuppressive and antiproliferative properties, and the use of SRL in kidney transplant recipients reduces the risk of post-transplant cancer. However, its use in advanced cancer patients has not been fully evaluated. The authors review the study by Cohen et al., evaluating the dose for oral, weekly SRL alone or in combination with grapefruit juice or ketoconazole to achieve the desired whole-blood concentration with antitumoral activity. This study demonstrates that SRL can be feasibly administered orally once weekly and displays a similar pharmacokinetic profile compared with other mTOR inhibitors. This study encouraged the use of SRL in advanced cancer patients and can stimulate clinical trials with a larger number of patients, evaluating the role of SRL as a new targeted therapy in cancer patients.

KW - cancer

KW - grapefruit juice

KW - ketoconazole

KW - once weekly

KW - oral

KW - sirolimus

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84871533702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871533702&partnerID=8YFLogxK

U2 - 10.1586/era.12.151

DO - 10.1586/era.12.151

M3 - Review article

C2 - 23259423

AN - SCOPUS:84871533702

VL - 13

SP - 17

EP - 20

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -